Amira makes appointments to scientific advisory board
This article was originally published in Scrip
Amira Pharmaceuticals, a US small molecule pharmaceutical company focused on the discovery and development of compounds to treat inflammatory diseases, has appointed Dr Paul Anderson, Professor Jerold Chun and Professor Andrew Tager to its scientific advisory board. Dr Anderson has more than 40 years' pharmaceutical research and managerial experience, including 30 years at Merck Research Laboratories. Dr Chun is a professor at The Scripps Research Institute in La Jolla, California, while Dr Tager is an assistant professor at Harvard Medical School in the pulmonary and critical care unit of the Massachusetts General Hospital, and co-director of the hospital's interstitial lung disease programme.
You may also be interested in...
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.
With many competitor programs on hold during the COVID crisis, L’Oreal dialed up its media investments and launched products over the summer that were postponed from the first quarter, resulting in a return to growth in the firm’s third quarter led by Professional Products and Active Cosmetics.
Just as the MDR and IVDR are being implemented, increasing regulatory divergence in Europe is a growing danger to patient safety throughout the EU. Erik Raadsheer, senior director of Align Technology, expressed concerns.